Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Chun, 2012, Isolated central nervous system progression on crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?, Cancer Biol Ther, 13, 1376, 10.4161/cbt.22255 Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539 FDA Approval for Ceritinib. https://www.cancer.gov/about-cancer/treatment/drugs/fda-ceritinib (March 2018, date last accessed). EMA Zykadia recommended for approval in advanced nonsmall-cell lung cancer. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/02/news_detail_002279.jsp&mid=WC0b01ac058004d5c1 (March 2018, date last accessed). Stenger, 2014 Zykadia™ (ceritinib) USPI, April 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755lbl.pdf (March 2018, date last accessed). Ou, 2016, Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study, J Clin Oncol, 34, 661, 10.1200/JCO.2015.63.9443 Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol, 17, 234, 10.1016/S1470-2045(15)00488-X Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N Engl J Med, 377, 829, 10.1056/NEJMoa1704795 FDA Approval for Alectinib. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584082.htm (March 2018, date last accessed). European Medicines Agency (EMA). European public assessment report (EPAR) for Alecensa. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004164/WC500225710.pdf; February 2017 (March 2018, date last accessed). Roche media release. https://www.roche.com/media/store/releases/med-cor-2017-10-13.htm (March 2018, date last accessed). Roche media release. https://www.roche.com/media/store/releases/med-cor-2017-11-07.htm (March 2018, date last accessed). Gadgeel, 2015, Pooled analysis of CNS response to alectinib in two studies of pre-treated ALK+ NSCLC, J Thorac Oncol, 10 Hida, 2017, Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial, Lancet, 390, 29, 10.1016/S0140-6736(17)30565-2 Johung, 2016, Extended survival and prognostic factors for patients with ALK-rearranged non–small-cell lung cancer and brain metastasis, J Clin Oncol, 34, 123, 10.1200/JCO.2015.62.0138 Zhang, 2015, Targeting brain metastases in ALK-rearranged non-small-cell lung cancer, Lancet Oncol, 16, e510, 10.1016/S1470-2045(15)00013-3 Guerin, 2015, Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy, Curr Med Res Opin, 31, 1587, 10.1185/03007995.2015.1057115 Ou, 2014, Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC, Ann Oncol, 25, 415, 10.1093/annonc/mdt572 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440 Shaw, 2017, Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 18, 874, 10.1016/S1470-2045(17)30339-X NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines), Non-Small Cell Lung Cancer, version 9.2017, October 17, 2017. https://www.cancer.gov/about-cancer/treatment/drugs/fda-ceritinib (March 2018, date last accessed).